Main Navigation

• The Children's Inn
• National Cancer Institute, Childhood Cancers
• NIH Clinical Center
• Camp Fantastic

Pediatric Oncology Branch Home > Scientific Programs > Pharmacology and Experimental Therapeutics Section and Genetic Tumor Predisposition Program > Staff > Holly Meany, MD

Headline Title

Pharmacology and Experimental Therapeutics Section and Genetic Tumor Predisposition Program: Staff

Holly Meany, MD

Dr Meany received her MD from Ohio State University College of Medicine and Public Health in Columbus, OH and completed her pediatric residency at Nationwide Children’s Hospital in Columbus and pediatric hematology/oncology fellowship at Children’s National Medical Center in Washington, DC. She joined the PET section in 2004 and her research has focused on the development of new agents for pediatric solid tumors and clinical trial design. She has developed and validated both pharmacokinetic and pharmacodynamic assays as part of active clinical treatment protocols. Dr Meany has a particular interest in neuroblastoma and is currently developing a phase 1 study of a new radio-labeled agent to be used in the treatment of this disease for high risk patients. Dr. Meany is a faculty member in the Division of Oncology at Children’s National Medical Center and continues to collaborate with the PET Section through a grant-funded position.

return to the top